| Name | Title | Contact Details |
|---|
Headquartered in the heart of Silicon Valley, California, VitalConnect was founded in 2011 with a vision of changing the paradigm of healthcare as we know it by creating a new world of information with predictive data analytics at everyone’s fingertips. VitalConnect provides physicians, nurses and patients with an extraordinary advancement in healthcare. Never before has so much continuous monitoring of vital signs been possible in a single, small—yet powerful—device. By consolidating eight critical vital signs into one wireless biosensor, VitalPatch enables a new view into healthcare, but more importantly it connects all interested parties in a patient’s recovery with each other. VitalConnect is also engaged in numerous partnerships with other leading medical device and pharmaceutical companies. It`s all about helping to bring a new paradigm and vision to fruition and providing the healthcare industry with the predictive data analytics it needs to reduce expenses, increase efficiency, provide better care—and most important of all, to save lives.
Alfa Wasserman is a Caldwell, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Heartsine Technologies is a Newtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
MEDIVATORS Conroe is a Conroe, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.